SEC Form 4 · accession 0001209191-17-046039
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandesh Mahatme
Officer — EVP, CFO & CBO
Period of report
Jul 20, 2017
Accepted (ET)
Jul 21, 2017 · 9:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 20, 2017 | M | 9,375 | $13.71 | A | 41,736 | D | |
| Common StockF1 | Jul 20, 2017 | S | 9,375 | $41.00 | D | 32,361 | D | |
| Common StockF1 | Jul 20, 2017 | M | 32,998 | $13.90 | A | 65,359 | D | |
| Common StockF1 | Jul 20, 2017 | S | 32,998 | $41.00 | D | 32,361 | D | |
| Common StockF2 | Jul 20, 2017 | M | 7,627 | $23.85 | A | 39,988 | D | |
| Common StockF2 | Jul 20, 2017 | S | 7,627 | $41.00 | D | 32,361 | D | |
| Common Stock | Jul 21, 2017 | M | 1,500 | $23.85 | A | 33,861 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F2 | $13.71 | Jul 20, 2017 | M | 9,375 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 9,375 | 24,591 | D |
| Non-Qualified Stock Options (right to buy)F2 | $13.90 | Jul 20, 2017 | M | 32,998 | D | Feb 27, 2016 | Feb 27, 2025 | Common Stock | 32,998 | 56,866 | D |
| Non-Qualified Stock Options (right to buy)F2 | $23.85 | Jul 20, 2017 | M | 7,627 | D | Nov 5, 2013 | Nov 5, 2022 | Common Stock | 7,627 | 125,605 | D |
| Incentive Stock Option (right to buy)F3 | $23.85 | Jul 21, 2017 | M | 1,500 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 1,500 | 14,268 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- F2This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 2, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- F325% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire.